SARS-CoV-2

Serosurveys to understand background immunity in the population to SARS-CoV-2

The Vaccine Research Group is conducting a serosurveillance study to assess antibody titers to coronaviruses in the U.S. population before the recent outbreak of SARS-CoV-2, the coronavirus that causes COVID-19. This study will enable us to measure population immunity to standard coronaviruses and the level of cross-reactivity with SARS-CoV-2. This study also will help us understand background immunity before the outbreak. The results also can be used to inform ongoing responses to the current SARS-CoV-2 outbreak.

Use of a technology pathway developed to identify immunologically relevant, SARS-CoV-2 pathogen-derived peptides that can be used for vaccine development and diagnostic kits

The Mayo Clinic Vaccine Research Group has developed a highly sensitive mass spectrometry-based approach to identifying pathogen-derived epitopes that antigen-presenting cells process and present to T cells. Each identified peptide is then evaluated to determine whether the immune system recognizes it and it contributes to immune protection. The results from these studies will help develop peptide- and subunit-based vaccines for SARS-CoV-2, and also may form the basis for diagnostic kits and platforms.

Learn more

See publications by Mayo Clinic authors related to SARS-CoV-2.

Learn about the diagnosis and treatment of COVID-19.